Hepion Pharmaceuticals, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Vincent LoPriore | 26.2% | 26,250,000 | SCHEDULE 13D/A, 2026-08-20 | 2026-08-03 |
| Black Global 5 LLC | 11.1% | 10,000,000 | SCHEDULE 13D, 2026-08-07 | 2026-07-31 |
| KI Holdings Ltd. | 10.2% | 10,000,000 | SCHEDULE 13D/A, 2026-09-16 | 2026-08-03 |
| Gary Stetz | 5.7% | 5,250,000 | SCHEDULE 13D, 2026-08-20 | 2026-08-03 |
| Sireesh Appajosyula | 5.7% | 5,250,000 | SCHEDULE 13D, 2026-08-20 | 2026-08-03 |
| Kenneth Rickel | 5.7% | 5,250,000 | SCHEDULE 13G, 2026-09-15 | 2026-08-03 |
| Anson Funds Management LP | 4.9% | 576,482 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| S.H.N. Financial Investments Ltd. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-08-14 |
Purpose of Transaction (Item 4)
Vincent LoPriore
The Common Stock owned by each of the Reporting Persons has been acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-20
Black Global 5 LLC
The Reporting Persons acquired the securities for investment purposes. The Reporting Persons intends to review its investment in the Issuer on a continuing basis. Depending upon market conditions, the Issuer's business, financial condition, prospects, general economic conditions and other factors deemed relevant, the Reporting Persons may acquire additional securities of the Issuer, dispose of some or all of its securities, or maintain its current investment position. Except as described herein, the Reporting Persons do not presently have any plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-07
Gary Stetz
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-20
Sireesh Appajosyula
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-20
KI Holdings Ltd.
The Reporting Person acquired the securities for investment purposes. The Reporting Person intends to review its investment in the Issuer on a continuing basis. Depending upon market conditions, the Issuer's business, financial condition, prospects, general economic conditions and other factors deemed relevant, the Reporting Persons may acquire additional securities of the Issuer, dispose of some or all of its securities, or maintain its current investment position. Except as described herein, the Reporting Person does not presently have any plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-09-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Anson Funds Management LP | 4.9% | SCHEDULE 13G/A |
| 2025-08-14 | S.H.N. Financial Investments Ltd. | 0% | SCHEDULE 13G/A |
| 2026-05-01 | Vincent LoPriore | 21.46% | SCHEDULE 13D |
| 2026-08-07 | Black Global 5 LLC | 11.1% | SCHEDULE 13D |
| 2026-08-20 | Gary Stetz | 5.7% | SCHEDULE 13D |
| 2026-08-20 | Sireesh Appajosyula | 5.7% | SCHEDULE 13D |
| 2026-08-20 | Vincent LoPriore | 26.2% | SCHEDULE 13D/A |
| 2026-09-15 | Kenneth Rickel | 5.7% | SCHEDULE 13G |
| 2026-09-16 | KI Holdings Ltd. | 10.2% | SCHEDULE 13D/A |
Hepion Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Hepion Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.